Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects.In this open-label, 52-week study, we randomly assigned 234 adult ...

Romiplostim’s approval was based on the results of a phase-3 trial published in 2008 in The Lancet. The trial included two parallel studies; one enrolled splenectomized patients, ...

Overview “Nplate (romiplostim)Romiplate - Drug Insight and Market Forecast – 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition ...

Romiplostim is initiated at a dosage of 1 µg/kg subcutaneously once weekly and titrated to achieve platelet counts between 50 and 200 x 10 9 platelets/L, with a maximum dose of 10 µg/kg.

Romiplostim is available in 250 mcg and 500 mcg single-use vials that must be reconstituted prior to use and then discarded. The drug acquisition cost may vary by institution, but will be around ...

Romiplostim was titrated with a target of 100,000 to 200,000/μL. In patients who responded to romiplostim (≥ 100,000/μL), weekly romiplostim was maintained to allow for resumption of chemotherapy as a ...

November 17, 2010 — Romiplostim may be more effective than standard of care for patients with immune thrombocytopenia (ITP), according to the results of an open-label, randomized study reported ...

THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Nplate (Romiplostim) Romiplate - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Nplate ...

The paper in the Nov. 11 New England Journal of Medicine reports that treatment with romiplostim, which mimics the effects of a growth factor that regulates platelet production, ...

In both RCTs, patients with ITP (defined as the mean of 3 platelet counts being below or equal to 30×10 9 per litre, with none of the 3 counts being above 35×10 9 per litre) whose condition was ...

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of romiplostim, having considered evidence on the nature of chronic ITP and the value placed on the ...